JP2010519174A - ｃ−Ｍｅｔの複素環阻害薬およびその使用方法 - Google Patents

ｃ−Ｍｅｔの複素環阻害薬およびその使用方法 Download PDF

Info

Publication number
JP2010519174A
JP2010519174A JP2009528341A JP2009528341A JP2010519174A JP 2010519174 A JP2010519174 A JP 2010519174A JP 2009528341 A JP2009528341 A JP 2009528341A JP 2009528341 A JP2009528341 A JP 2009528341A JP 2010519174 A JP2010519174 A JP 2010519174A
Authority
JP
Japan
Prior art keywords
aliphatic
optionally substituted
ring
cancer
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009528341A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010519174A5 (cg-RX-API-DMAC7.html
Inventor
アレクサンダー アロノフ，
ジョン コーム，
ジョン コート，
デイビッド デイニンガー，
デイビッド ローファー，
パン リー，
キラ マクギンティー，
スガンシニ ナンサクマー，
ディーン スタモス，
カーク タナー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2010519174A publication Critical patent/JP2010519174A/ja
Publication of JP2010519174A5 publication Critical patent/JP2010519174A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2009528341A 2006-09-18 2007-09-18 ｃ−Ｍｅｔの複素環阻害薬およびその使用方法 Pending JP2010519174A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84535606P 2006-09-18 2006-09-18
PCT/US2007/020222 WO2008036272A1 (en) 2006-09-18 2007-09-18 HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF

Publications (2)

Publication Number Publication Date
JP2010519174A true JP2010519174A (ja) 2010-06-03
JP2010519174A5 JP2010519174A5 (cg-RX-API-DMAC7.html) 2010-11-04

Family

ID=39092942

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009528341A Pending JP2010519174A (ja) 2006-09-18 2007-09-18 ｃ−Ｍｅｔの複素環阻害薬およびその使用方法

Country Status (9)

Country Link
US (1) US8481538B2 (cg-RX-API-DMAC7.html)
EP (1) EP2066676A1 (cg-RX-API-DMAC7.html)
JP (1) JP2010519174A (cg-RX-API-DMAC7.html)
CN (1) CN101796056A (cg-RX-API-DMAC7.html)
AU (1) AU2007297754B2 (cg-RX-API-DMAC7.html)
CA (1) CA2663528A1 (cg-RX-API-DMAC7.html)
MX (1) MX2009002842A (cg-RX-API-DMAC7.html)
NZ (1) NZ575548A (cg-RX-API-DMAC7.html)
WO (1) WO2008036272A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX393622B (es) * 2008-05-21 2025-03-24 Incyte Corp Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas.
US20120065205A1 (en) * 2009-06-01 2012-03-15 Mercer Swati P Pyrazine carboxamide orexin receptor antagonists
PL2719699T3 (pl) 2009-12-31 2016-01-29 Hutchison Medipharma Ltd Pewne triazolopirazyny, ich kompozycje i sposoby ich stosowania
EP2571878B1 (en) 2010-05-17 2018-10-17 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases
MX359888B (es) 2012-03-30 2018-10-15 Rhizen Pharmaceuticals Sa Novedosos compuestos de 3h-imidazo [4,5-b] piridina 3,5-disubstituida y 3h- [1,2,3] triazolo [4,5-b] piridina 3,5-disubstituida como moduladores de c-met proteina cinasas.
AR101106A1 (es) * 2014-07-02 2016-11-23 Pharmacyclics Llc Inhibidores de tirosina quinasa de bruton
US20180194769A1 (en) 2015-07-06 2018-07-12 Rodin Therapeutics, Inc. Hetero-halo inhibitors of histone deacetylase
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
JP6756925B2 (ja) 2017-01-11 2020-09-16 ロダン・セラピューティクス，インコーポレーテッド ヒストンデアセチラーゼの二環式阻害剤
SMT202200232T1 (it) 2017-08-07 2022-07-21 Alkermes Inc Inibitori biciclici di istone deacetilasi
WO2020118683A1 (en) * 2018-12-14 2020-06-18 Lynk Pharmaceuticals Co. Ltd. Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
TR202010296A1 (tr) * 2020-06-30 2022-01-21 Anadolu Ueniversitesi Akt inhibisyonu aracılığıyla a549 hücrelerinde sitotoksik ve apoptotik etki gösteren yeni triazol ve triazolotiyadiazin türevleri

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083481A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
WO2005010005A1 (en) * 2003-07-02 2005-02-03 Sugen, Inc. Triazolotriazine compounds and uses thereof
JP2006513208A (ja) * 2002-12-18 2006-04-20 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼインヒビターとしてのトリアゾロピリダジン

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5144532B2 (ja) * 2005-11-30 2013-02-13 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−Ｍｅｔ阻害剤及び用法
WO2008060578A2 (en) * 2006-11-15 2008-05-22 Cytovia, Inc. 3-aryl-6-aryl-[1,2,4] triazolo[3,4-b][1,3,4] thiadiazoles and related compounds as activators of caspases and inducers of apoptosis and the use thereof
US20110044943A1 (en) * 2007-07-13 2011-02-24 Martin Robert Leivers Anti-Viral Compounds, Compositions, And Methods Of Use
AU2009211887B2 (en) * 2008-02-05 2013-09-19 Sanofi Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments
AU2010226490A1 (en) * 2009-03-20 2011-10-06 Amgen Inc. Inhibitors of PI3 kinase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083481A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
JP2006513208A (ja) * 2002-12-18 2006-04-20 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼインヒビターとしてのトリアゾロピリダジン
WO2005010005A1 (en) * 2003-07-02 2005-02-03 Sugen, Inc. Triazolotriazine compounds and uses thereof

Also Published As

Publication number Publication date
NZ575548A (en) 2011-09-30
WO2008036272A1 (en) 2008-03-27
US8481538B2 (en) 2013-07-09
CA2663528A1 (en) 2008-03-27
EP2066676A1 (en) 2009-06-10
CN101796056A (zh) 2010-08-04
AU2007297754A1 (en) 2008-03-27
AU2007297754B2 (en) 2012-05-17
MX2009002842A (es) 2009-05-27
US20100144739A1 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
JP5144532B2 (ja) ｃ−Ｍｅｔ阻害剤及び用法
JP2010519174A (ja) ｃ−Ｍｅｔの複素環阻害薬およびその使用方法
EP1881983B1 (en) Pyrrolopyridines useful as inhibitors of protein kinase
EP2032562B1 (en) Selective inhibitors of rock protein kinase and uses thereof
JP2009532475A (ja) ヤヌスキナーゼの阻害剤として有用なデアザプリン
JP2010508363A (ja) ヤヌスキナーゼの阻害剤として有用な三環系ヘテロアリール化合物
NZ575346A (en) 5- (2-furyl)-1, 3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase
JP2012519177A (ja) 三環式ピラゾロピリジンキナーゼインヒビター
JP2012529525A (ja) ホスファチジルイノシトール３−キナーゼの阻害薬
JP2011518168A (ja) ホスファチジルイノシトール３−キナーゼの阻害薬
EP2488511A1 (en) Pyrazole inhibitors of phosphatidylinositol 3-kinase
HK1146825A (en) Heterocyclic inhibitors of c-met and uses thereof
HK1125106A (en) Inhibitors of c-met and uses thereof
HK1155440A (en) Inhibitors of phosphatidylinositol 3-kinase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100916

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110907

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20121127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130513